Nephrotoxicity of amphotericin B is attenuated by solubilizing with lipid emulsion

Journal of the American Society of Nephrology

Volumn 8, Issue 9, 1997, Pages 1415-1422

  Dórea, Egidio Lima ^a,b   Yu, Luis ^a   De Castro, Isac ^a   Campos, Sílvia Bernadette ^a   Ori, Maria ^a   Vaccari, Elisabeth Maria Heins ^a   Da Silva Lacaz, Carlos ^a   Seguro, Antonio Carlos ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Apartment 33   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; DEOXYCHOLATE SODIUM; LACTATE DEHYDROGENASE; LIPID EMULSION;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG MIXTURE; INTRAPERITONEAL DRUG ADMINISTRATION; KIDNEY BLOOD FLOW; KIDNEY FUNCTION; MALE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0343118179     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/asn.v891415     Document Type: Article

References (36)

1. Gallis HA, Drew RH, Pickard WW: Amphotericin B: 30 years of clinical experience. Rev Infect Dis 12: 308-329, 1990
2. Utz JP: Amphotericin B toxicity: General side effects. Ann Intern Med 61: 340-343, 1964
3. Buttler WT, Bennet JE, Alling DW, Wertlake PT, Utz JP, Hill GJ: Nephrotoxicity of amphotericin B: Early and late effects in 81 patients. Ann Intern Med 61: 175-187, 1964
4. Cheng JT, Witty RT, Robinson RR, Yarger WE: Amphotericin B nephrotoxicity: Increased renal resistance and tubule permeability. Kidney Int 22: 626-633, 1982
5. Andreoli TE, Monahan M: The interaction of polyene antibiotics with thin lipid membranes. J Gen Physiol 52: 300-325, 1968
6. Hoeprich PD: Amphotericin B methyl ester and leukoencephalopathy: The other side of the coin. J Infect Dis 146: 173-176, 1982
7. Mehta R, Lopez-Berestein G, Hopfer R, Mills K, Juliano RL: Liposomal amphotericin B is toxic to fungal cells but not to mammalian cells. Biochim Biophys Acta 770: 230-234, 1984
8. Janoff AS, Boni LT, Popescu MC, Minchey SR, Cullis PR, Madden TD, Taraschi T, Gruner SM, Shyamsunder E, Tate MW, Mendelsohn R, Bonner D: Unusual lipid structures selectively reduce the toxicity of amphotericin B. Proc Natl Acad Sci USA 85: 6122-6126, 1988
9. Joly V, Dromer F, Barge J, Yeni P, Seta N, Molas G, Carbon C: Incorporation of amphotericin B (AMB) into liposomes alters AMB-induced acute nephrotoxicity in rabbits. J Pharmacol Exp Ther 251: 311-316, 1989
10. Meunier F, Prentice HG, Ringdén O: Liposomal amphotericin B (AmBisome): Safety data from a phase II/III clinical trial. J Antimicrob Chemother 28[Suppl B]: 83-91, 1991
11. Kirsh R, Goldstein R, Tarloff J, Parris D, Hook J, Hanna N, Bugelski P, Poste G: An emulsion formulation of amphotericin B improves the therapeutic index when treating systemic murine candidiasis. J Infect Dis 158: 1065-1070, 1988
12. Moreau P, Milpied N, Fayette N, Ramée JF, Harousseau JL: Reduced renal toxicity and improved clinical tolerance of amphotericin B mixed with intralipid compared with conventional amphotericin B in neutropenic patients. J Antimicrob Chemother 30: 535-541, 1992
13. Yu L, Gengaro PE, Niederberger M, Burke TJ, Schrier RW: Nitric oxide: A mediator in rat tubular hypoxia/reoxygenation injury. Proc Natl Acad Sci USA 91: 1691-1695, 1994
14. Bergmeyer HV: Methods in Enzymatic Analysis, 2nd Ed., New York, Academic Press, 1974, pp 574-589
15. Beutler E: Lactate dehydrogenase (LDH). In: Red Cell Metabolism: A Manual of Biochemical Methods, 3rd Ed., edited by Beutler E, New York, Grune & Stratton, 1984, pp 65-66
16. Caillot D, Reny G, Solary E, Casasnovas O, Chavanet P, Bonnotte B, Perello L, Dumas M, Fahrad E, Guy H: A controlled trial of the tolerance of amphotericin B infused in dextrose or in intralipid in patients with haematological malignancies. J Antimicrob Chemother 33: 603-613, 1994
17. Levine SJ, Walsh TJ, Martinez A, Eichacker PQ, Lopez-Berestein G, Natanson C: Cardiopulmonary toxicity after liposomal amphotericin B infusion. Ann Intern Med 114: 664-666, 1991
18. Gouge TH, Andriole VT: An experimental model of amphotericin B nephrotoxicity with renal tubular acidosis. J Lab Clin Med 78: 713-724, 1971
19. Sawaya BP, Weihprecht H, Campbell WR, Lorenz JN, Webb RC, Briggs JP, Schnermann J: Direct vasoconstriction as a possible cause for amphotericin B-induced nephrotoxicity in rats. J Clin Invest 87: 2097-2107, 1991
20. Sawaya BP, Briggs JP, Schnermann J: Amphotericin B nephrotoxicity: The adverse consequences of altered membrane properties. J Am Soc Nephrol 6: 154-164, 1995
21. Bell NH, Andriole VT, Sabesin SM, Utz JP: On the nephrotoxicity of amphotericin B in man. Am J Med 33: 64-69, 1962
22. Yano Y, Monteiro JL, Seguro AC: Effect of amphotericin B on water and urea transport in the inner medullary collecting duct. J Am Soc Nephrol 5: 68-74, 1994
23. McCurdy DK, Frederic M, Elkinton JR: Renal tubular acidosis due to amphotericin B. N Engl J Med 278: 124-131, 1968
24. Steinmetz PR, Lawson LR: Defect in urinary acidification induced in vitro by amphotericin B. J Clin Invest 49: 596-601, 1970
25. Sanford WG, Rasch JR, Stonehill RB: The treatment of disseminated coccidioidomycosis with amphotericin. Ann Intern Med 56: 553-563, 1962
26. Llanos A, Cieza J, Bernardo J, Echevarria J, Biaggioni I, Sabra R, Branch RA: Effect of salt supplementation on amphotericin B nephrotoxicity. Kidney Int 40: 302-308, 1991
27. Zager RA, Bredl CR, Schimpf BA: Direct amphotericin B-mediated tubular toxicity: Assessments of selected cytoprotective agents. Kidney Int 41: 1588-1594, 1992
28. Christiansen KJ, Bernard EM, Gold JWM, Armstrong D: Distribution and activity of amphotericin B in humans. J Infect Dis 152: 1037-1043, 1985
29. Walev I, Bhakdi S: Possible reason for preferential damage to renal tubular epithelial cells evoked by amphotericin B. Antimicrob Agents Chemother 40: 1116-1120, 1996
30. Colombo AL, Barchiesi F, McGough DA, Rinaldi MG: Comparison of Etest and National Committee for Clinical Laboratory Standards Broth Macrodilution Method for Azole Antifungal Susceptibility Testing. J Clin Microbiol 33: 535-540, 1995
31. Espinel-Ingroff A, Pfaller M, Erwin ME, Jones RN: Interlaboratory evaluation of Etest method for testing antifungal susceptibilities of pathogenic yeasts to five antifungal agents by using casitone agar and solidified RPMI 1640 medium with 2% glucose. J Clin Microbiol 34: 848-852, 1996
32. Joly V, Farinotti R, Saint-Julien L, Chéron M, Carbon C, Yeni P: In vitro renal toxicity and in vivo therapeutic efficacy in experimental murine cryptococcosis of amphotericin B (Fungizone) associated with intralipid. Antimicrob Agents Chemother 38: 177-183, 1994
33. Caillot D, Casasnovas O, Solary E, Pascal C, Bonnotte B, Reny G, Entezam F, Lopez J, Bonnin A, Guy H: Efficacy and tolerance of an amphotericin B lipid (intralipid) emulsion in the treatment of candidaemia in neutropenic patients. J Antimicrob Chemother 31: 161-169, 1993
34. Sorkine P, Nagar H, Weinbroum A, Setton A, Israitel E, Scarlatt A, Silbiger A, Rudick V, Kluger Y, Halpern P: Administration of amphotericin B in lipid emulsion decreases nephrotoxicity: Results of a prospective, randomized, controlled study in critically ill patients. Crit Care Med 24: 1311-1315, 1996
35. Szoka FC, Milholland D, Barza M: Effect of lipid composition and liposome size on toxicity and in vitro fungicidal activity of liposome-intercalated amphotericin B. Antimicrob Agents Chemother 31: 421-429, 1987
36. Krause HJ, Juliano RL: Interactions of liposome-incorporated amphotericin B with kidney epithelial cell cultures. Mol Pharmacol 34: 286-297, 1988